SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 3, 2012, Pages 441-448

  Sortica, Vinicius A ^a   Fiegenbaum, Marilu ^b   Lima, Luciana O ^b   Van Der Sand, Czar R ^c   Van Der Sand, Luis C ^c   Ferreira, Maria E W ^c   Pires, Renan C ^c   Hutz, Mara H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Nutrition Research Group NUPEN   (Brazil)

^c Centro de Diagnstico Cardiolgico   (Brazil)

Author keywords

OATP1B1; pharmaco genetics; simvastatin; SLCO1B1

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORGANIC ANION TRANSPORTER 2; SIMVASTATIN;

ADULT; AGED; ARTICLE; BRAZIL; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTICHOLESTEREMIC AGENTS; BRAZIL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84860494214     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.2011.804     Document Type: Article

References (44)

1. Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther 2007;21:297-309. (Pubitemid 47387466)
2. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
3. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar ? Pharmacol Ther 1998;80:1-34 (Pubitemid 28498199)
4. Schmitz G, Langmann T. Pharmacogenomics of cholesterol-lowering therapy. Vascul Pharmacol 2006;44:75-89. (Pubitemid 43082209)
5. Za ï r ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 2008;9:597-624.
6. Maitland-van der Zee AH, Klungel OH, Stricker BH, Verschuren WM, Kastelein JJ, Leufkens HG, et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002;163:213-22. (Pubitemid 34615811)
7. Meier-Abt F, Mokrab Y, Mizuguchi K. Organic anion transporting polypeptides of the OATP/SLCO superfamily: identifi cation of new members in non-mammalian species, comparative modeling and a potential transport mode. J Membr Biol 2005;208:213-27.
8. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81.
9. Franke RM, Scherkenbach LA, Sparreboom A. Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 2009;10:339-44.
10. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 2002;277:43058-63. (Pubitemid 35285687)
11. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-979.
12. Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The infl uence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010;10:1-11.
13. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007;8:787-802. (Pubitemid 47288978)
14. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identifi cation of multiple allelic variants associated with altered transport activity among European- and African- Americans. J Biol Chem 2001;276:35669-75.
15. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14:429-40. (Pubitemid 38971233)
16. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9:19-33. (Pubitemid 351560529)
17. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008;21:789-99.
18. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B15 genetic variant is associated with statininduced side effects. J Am Coll Cardiol 2009;54:1609-16.
19. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003;304:223-8. (Pubitemid 36008932)
20. Oswald S, Konig J, Lutjohann D, Giessmann T, Kroemer HK, Rimmbach C, et al. Disposition of ezetimibe is infl uenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenetics Genomics 2008;18:559-68.
21. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1 5, SLCO1B1 15 and SLCO1B1 15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005;15:513-22. (Pubitemid 41017600)
22. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002;302:804-13. (Pubitemid 34787251)
23. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005;33:434-9. (Pubitemid 40279945)
24. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004;14:749-57. (Pubitemid 39552790)
25. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793-806.
26. Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, et al. Organic anion transporting polypeptide 1B1 activity classifi ed by SLCO1B1 genotype infl uences atrasentan pharmacokinetics. Clin Pharmacol Ther 2006;79:186-96.
27. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003;73:554-65. (Pubitemid 37249126)
28. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005;78:342-50.
29. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330-41. (Pubitemid 41393668)
30. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82:726-33. (Pubitemid 350114817)
31. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fl uvastatin. Clin Pharmacol Ther 2006;80:356-66. (Pubitemid 44465886)
32. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004;19:375-80.
33. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, et al. SLCO1B1 521T-?C functional genetic polymorphism and lipid-lowering effi cacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 2007;64:346-52. (Pubitemid 47283861)
34. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering effi cacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006;79:419-26.
35. Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fl uvastatin therapy. Pharmacogenomics 2008;9:1217-27.
36. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering effi - cacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005;78:551-8. (Pubitemid 41698910)
37. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
38. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991;19:5444.
39. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995;56:799-810.
40. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006;79:427-39.
41. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004;75:415-21. (Pubitemid 38534562)
42. Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K, et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006;51:822-6. (Pubitemid 44386828)
43. Pernerger TV. What's wrong with Bonferroni adjustments. Br Med J 1998;316:1236-8.
44. Santos NP, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AK, Pereira R, Gusm ã o L, Amorim A, et al. Assessing individual interethnic admixture and population substructure using a 48-insertion- deletion (INSEL) ancestry-informative marker (AIM) panel. Hum Mutat 2010;31:184-90.